期刊
UROLOGY
卷 89, 期 -, 页码 27-32出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.urology.2015.11.034
关键词
-
资金
- AbbVie
- Bayer
- Clarus
- Endo
- Eli Lilly
- Pfizer
Testosterone therapy (TTh) has become highly controversial. There are important health consequences of testosterone deficiency, and meaningful benefits with treatment. There is level 1 evidence that TTh improves sexual function and desire, body composition, and bone density. Concerns regarding cardiovascular risk were based on two deeply flawed retrospective studies and are contradicted by dozens of studies showing cardiovascular benefits of TTh or higher endogenous testosterone, including placebo-controlled studies in men with known heart disease (angina, heart failure). Prostate cancer should no longer be considered a risk of TTh. Testosterone is neither scourge nor panacea-it is just good medicine. (C) 2016 Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据